Amgen Inc. vs Gilead Sciences, Inc. — Stock Comparison
Amgen Inc. (AMGN) and Gilead Sciences, Inc. (GILD) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Amgen Inc. scores ahead of Gilead Sciences, Inc. on Q·Score (7.1 vs 5.8 out of 10), led by Quality (9.3 vs 2.7) and Growth (8.9 vs 7.1). Gilead Sciences, Inc. scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for GILD (+9.2%) than for AMGN (+2.6%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 91% return on equity and 23% profit margins.
⚠ high leverage at 4.9× debt-to-equity.
75% of 28 covering analysts have a positive rating.
⚠ currently unprofitable (-11% margin).
Analyst Consensus
Fundamentals
Frequently Asked Questions
AMGN vs GILD: which stock scores better overall?
Based on Q·Score, Amgen Inc. (AMGN) scores 7.1/10 versus Gilead Sciences, Inc. (GILD) at 5.8/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: AMGN or GILD?
Amgen Inc. (AMGN) scores higher on Growth (8.9/10 vs 7.1/10). Amgen Inc. reports revenue growth (9.5% YoY) while Gilead Sciences, Inc. reports (10.2% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is AMGN or GILD more attractively valued?
Gilead Sciences, Inc. (GILD) scores higher on Valuation (7.3/10 vs 6.8/10). AMGN trades at 15.5× P/E versus GILD at 14.7×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about AMGN vs GILD?
There are 29 analysts covering AMGN with a consensus price target of $388.03, and 27 analysts covering GILD with a consensus target of $158.15. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: AMGN or GILD?
Amgen Inc. (AMGN) scores higher on Quality (9.3/10 vs 2.7/10). Net profit margin: AMGN at 23.0%, GILD at -10.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: AMGN or GILD?
Gilead Sciences, Inc. (GILD) scores higher on Financial Health (5.5/10 vs 4.5/10). Market beta: AMGN at 0.43, GILD at 0.35. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of AMGN and GILD?
Amgen Inc. (AMGN) has a market capitalisation of $204.4B, while Gilead Sciences, Inc. (GILD) has a market cap of $179.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do AMGN or GILD pay dividends?
AMGN pays a dividend yield of 2.64%, while GILD pays a dividend yield of 2.28%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →